Photo of Whitfield Board Growdon,  MD

Whitfield Board Growdon, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4800

Whitfield Board Growdon, MD

Massachusetts General Hospital


  • Assistant Professor, Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
  • Clinical Assistant in Obstetrics, Gynecology and Reproductive Biology, Obstetrics and Gynecology, Massachusetts General Hospital


Research Abstract

As a resident, fellow and now a faculty member in the Division of Gynecologic Oncology at Massachusetts General Hospital, I have been committed to providing innovative clinical care, conducting translational research and developing my leadership as an educator. Half of my effort is devoted to clinical activities where I strive to utilize innovative surgical techniques, including single incision laparoscopy and robotic surgery, in the care of my patients with cervical, endometrial and ovarian cancer. The remainder of my time is dedicated to translational research and educational activities.

My area of excellence has been in the arena of translational science that seeks to define targets for novel cancer therapeutics. I currently work within an interdisciplinary team to discover molecular signatures that identify sub-populations of patients that may benefit from specific therapies in gynecologic cancers. My recent investigations focus on both rare cancers, such as vulvar cancer and carcinosarcomas, as well as more common GYN cancers including endometrial and ovarian. We have described molecular fingerprints, such as epidermal growth factor receptor (EGFR) gene amplification or PIK3CA mutations in subsets of these tumors that may confer sensitivity to emerging novel therapies. I aspire to expand this work and complement an ongoing personalized medicine program between the VCRB, the MGH Translational Laboratory and the Dana Farber/Harvard Cancer Center. To realize this agenda, I have acquired experience in multiple technologies including fluorescence in situ hybridization (FISH), high-throughput genotyping, mouse xenograft modeling, immunohistochemistry (IHC), and array comparative genomic hybridization (aCGH). My future goal is to identify therapeutically-relevant molecular signatures in ovarian and endometrial cancers and use these fingerprints to design clinical trials that tailor treatment strategies for the individual patients. I have received an institutional K12 grant through the Proton Beam System that will support my investigations on high grade endometrial cancer with a planned clinical trial that incorporates scientific endpoints to understand observed response rates.


Powered by Harvard Catalyst
  • Melamed A, Nitecki R, Boruta DM, Del Carmen MG, Clark RM, Growdon WB, Goodman A, Schorge JO, Rauh-Hain JA. Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy. Obstet Gynecol 2017. PubMed
  • Bregar A, Deshpande A, Grange C, Zi T, Stall J, Hirsch H, Reeves J, Sathyanarayanan S, Growdon WB, Rueda BR. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecol Oncol 2017. PubMed
  • Diver E, Hinchcliff E, Gockley A, Melamed A, Contrino L, Feldman S, Growdon W. Minimally Invasive Radical Hysterectomy for Cervical Cancer Is Associated with Reduced Morbidity and Similar Survival Outcomes Compared with Laparotomy. J Minim Invasive Gynecol 2016. PubMed
  • Bigelow CA, Horowitz NS, Goodman A, Growdon WB, Del Carmen M, Kaimal AJ. Management and outcome of cervical cancer diagnosed in pregnancy. Am J Obstet Gynecol 2016. PubMed
  • Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA, Banerji A. Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. J Allergy Clin Immunol Pract 2016. PubMed
  • Lee MS, Venkatesh KK, Growdon WB, Ecker JL, York-Best CM. Predictors of 30-day readmission following hysterectomy for benign and malignant indications at a tertiary care academic medical center. Am J Obstet Gynecol 2016; 214:607.e1-607.e12. PubMed
  • Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR, Growdon WB. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation. Gynecol Oncol 2016. PubMed
  • Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, Del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecol Oncol 2016; 141:108-12. PubMed
  • Garrett LA, Growdon WB, Rueda BR, Foster R. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. 2016; 9:58. PubMed
  • Diver EJ, Foster R, Rueda BR, Growdon WB. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. Oncologist 2015. PubMed
  • Dong F, Kojiro S, Borger DR, Growdon WB, Oliva E. Squamous Cell Carcinoma of the Vulva: A Subclassification of 97 Cases by Clinicopathologic, Immunohistochemical, and Molecular Features (p16, p53, and EGFR). Am J Surg Pathol 2015; 39:1045-53. PubMed
  • Joseph N, Clark RM, Dizon DS, Lee MS, Goodman A, Boruta D, Schorge JO, Del Carmen MG, Growdon WB. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecol Oncol 2015. PubMed
  • Ghezelayagh T, Rauh-Hain JA, Growdon WB. Comparing mortality of vaginal sarcoma, squamous cell carcinoma, and adenocarcinoma in the surveillance, epidemiology, and end results database. Obstet Gynecol 2015; 125:1353-61. PubMed
  • Growdon WB, Groeneweg J, Byron V, DiGloria C, Borger DR, Tambouret R, Foster R, Chenna A, Sperinde J, Winslow J, Rueda BR. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant. Gynecol Oncol 2015; 137:160-6. PubMed
  • Aviki EM, Rauh-Hain JA, Clark RM, Hall TR, Berkowitz LR, Boruta DM, Growdon WB, Schorge JO, Goodman A. Gynecologic Oncologist as surgical consultant: intraoperative consultations during general gynecologic surgery as an important focus of gynecologic oncology training. Gynecol Oncol 2015; 137:93-7. PubMed
  • Clark RM, Lee MS, Alejandro Rauh-Hain J, Hall T, Boruta DM, del Carmen MG, Goodman A, Schorge JO, Growdon WB. Surgical Apgar Score and prediction of morbidity in women undergoing hysterectomy for malignancy. Gynecol Oncol 2015; 136:516-20. PubMed
  • Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, Kim M, Zhang L, Borger DR, Tambouret R, Foster R, Rueda BR, Growdon WB. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts. Clin Cancer Res 2014. PubMed
  • Clark RM, Lynch MP, Kolp R, Zukerberg LR, Growdon WB, Rueda BR. The N-methyl-D-aspartate receptor, a precursor to N-methyl-D-aspartate receptor encephalitis, is found in the squamous tissue of ovarian teratomas. Int J Gynecol Pathol 2014; 33:598-606. PubMed
  • Groeneweg JW, Hall TR, Zhang L, Kim M, Byron VF, Tambouret R, Sathayanrayanan S, Foster R, Rueda BR, Growdon WB. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model. Gynecol Oncol 2014. PubMed
  • Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB, Schorge JO, Del Carmen MG, Horowitz NS, Boruta DM. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol 2014; 133:216-20. PubMed
  • Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecol Oncol 2014; 133:346-52. PubMed
  • Foley OW, Rauh-Hain JA, Clark RM, Goodman A, Growdon WB, Boruta DM, Schorge JO, Del Carmen MG. Intraoperative Radiation Therapy in the Management of Gynecologic Malignancies. Am J Clin Oncol 2014. PubMed
  • Guseh SH, Rauh-Hain JA, Tambouret RH, Davis M, Clark RM, Boruta DM, Goodman A, Growdon WB, Schorge JO, del Carmen MG. Transitional cell carcinoma of the ovary: a case-control study. Gynecol Oncol 2014; 132:649-53. PubMed
  • Rauh-Hain JA, Vargas RJ, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, Boruta DM, Schorge JO, Del Carmen MG. Mucinous Adenocarcinoma of the Endometrium Compared With Endometrioid Endometrial Cancer: A SEER Analysis. Am J Clin Oncol 2014. PubMed
  • Groeneweg JW, Foster R, Growdon WB, Verheijen RH, Rueda BR. Notch signaling in serous ovarian cancer. 2015; 7:95. PubMed
  • Groeneweg JW, DiGloria CM, Yuan J, Richardson WS, Growdon WB, Sathyanarayanan S, Foster R, Rueda BR. Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth. 2014; 4:171. PubMed
  • Rauh-Hain JA, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, Boruta DM, Schorge JO, del Carmen MG. Racial disparities and changes in clinical characteristics and survival for vulvar cancer over time. Am J Obstet Gynecol 2013; 209:468.e1-468.e10. PubMed
  • Rauh-Hain JA, Davis M, Clemmer J, Clark RM, Growdon WB, Goodman AK, Boruta DM, Schorge JO, del Carmen MG. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis. Gynecol Oncol 2013; 131:404-9. PubMed
  • Rauh-Hain JA, Clemmer JT, Bradford LS, Clark RM, Growdon WB, Goodman A, Boruta DM, Schorge JO, del Carmen MG. Racial disparities in cervical cancer survival over time. Cancer 2013; 119:3644-52. PubMed
  • Rauh-Hain JA, Diver EJ, Clemmer JT, Bradford LS, Clark RM, Growdon WB, Goodman AK, Boruta DM, Schorge JO, del Carmen MG. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol 2013; 131:46-51. PubMed
  • Clark RM, Growdon WB, Wiechert A, Boruta D, Del Carmen M, Goodman AK, Bradford L, Rauh-Hain A, Schorge JO. Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgical cytoreduction for epithelial ovarian carcinoma. Gynecol Oncol 2013; 130:407-10. PubMed
  • Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23:1219-25. PubMed
  • Maestá I, Growdon WB, Goldstein DP, Bernstein MR, Horowitz NS, Rudge MV, Berkowitz RS. Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 2013; 130:312-6. PubMed
  • Penson RT, Goodman A, Growdon WB, Borger DR, Lee SI, Oliva E. Case records of the Massachusetts General Hospital. Case 14-2013. A 70-year-old woman with vaginal bleeding. N Engl J Med 2013; 368:1827-35. PubMed
  • May T, Shoni M, Vitonis AF, Quick CM, Growdon WB, Muto MG. The role of para-aortic lymphadenectomy in the surgical staging of women with intermediate and high-risk endometrial adenocarcinomas. Int J Surg Oncol 2013; 2013:858916. PubMed
  • Rauh-Hain JA, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, Berkowitz RS, Horowitz NS, Del Carmen MG. Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol 2012. PubMed
  • Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM, Horowitz NS, del Carmen MG, Schorge JO. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol 2012. PubMed
  • Growdon WB, Rauh-Hain JJ, Cordon A, Garrett L, Schorge JO, Goodman A, Boruta DM, Horowitz NS, del Carmen MG. Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. Int J Gynecol Cancer 2012; 22:417-24. PubMed
  • Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Allred SF, Gross J, Deavers MT, Kuo WL, Karlan BY, Rueda BR, Orsulic S, Gershenson DM, Birrer MJ, Gray JW, Mohapatra G. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS ONE 2012; 7:e30996. PubMed
  • Growdon WB. Age and postmenopausal bleeding risk factors for malignant changes in endometrial polyps. Menopause 2011; 18:1267. PubMed
  • Boruta DM, Growdon WB, McCann CK, Garrett LA, del Carmen MG, Goodman A, Schorge JO. Evolution of surgical management of early-stage endometrial cancer. Am J Obstet Gynecol 2011. PubMed
  • McCann CK, Growdon WB, Munro EG, Del Carmen MG, Boruta DM, Schorge JO, Goodman A. Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer. Ann Surg Oncol 2011. PubMed
  • Esselen KM, Boruta DM, del Carmen M, Schorge JO, Goodman A, Growdon WB. Defining prognostic variables in recurrent endometrioid endometrial cancer: a 15-year single-institution review. Int J Gynecol Cancer 2011; 21:1078-83. PubMed
  • Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol 2011; 121:212-7. PubMed
  • McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, Sheikh H, Deyneko I, Ferguson JA, Vathipadiekal V, Birrer MJ, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Macdougall JR, Rueda BR. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS ONE 2011; 6:e28077. PubMed
  • Weber S, McCann CK, Boruta DM, Schorge JO, Growdon WB. Laparoscopic surgical staging of early ovarian cancer. Rev Obstet Gynecol 2012; 4:117-22. PubMed
  • Rauh-Hain JA, Growdon WB, Schorge JO, Goodman AK, Boruta DM, McCann C, Horowitz NS, del Carmen MG. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol 2010; 119:299-304. PubMed
  • Friel AM, Growdon WB, McCann CK, Olawaiye AB, Munro EG, Schorge JO, Castrillon DH, Broaddus RR, Rueda BR. Mouse models of uterine corpus tumors: clinical significance and utility. Front Biosci (Elite Ed) 2010; 2:882-905. PubMed
  • Growdon WB,Boisvert SL,Akhavanfard S,Oliva E,Dias-Santagata DC,Kojiro S,Horowitz NS,Iafrate AJ,Borger DR,Rueda BR. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol 2008; 111:289-97. PubMed
  • Dantas PR, Maestá I, Cortés-Charry R, Growdon WB, Braga A, Rudge MV, Berkowitz RS. Influence of hydatidiform mole follow-up setting on postmolar gestational trophoblastic neoplasia outcomes: a cohort study. J Reprod Med 2012; 57:305-9. PubMed
  • Braga A, Growdon WB, Bernstein M, Maestá I, Rudge MV, Goldstein DP, Berkowitz RS. Molar pregnancy in adolescents. J Reprod Med 2012; 57:225-30. PubMed
  • Rauh-Hain JA, Growdon WB, Braga A, Goldstein DP, Berkowitz RS. Gestational trophoblastic neoplasia in adolescents. J Reprod Med 2012; 57:237-42. PubMed
  • Garrett LA, Growdon WB, Goodman A, Boruta DM, Schorge JO, del Carmen MG. Endometriosis-associated ovarian malignancy: a retrospective analysis of presentation, treatment, and outcome. J Reprod Med 2014; 58:469-76. PubMed
  • Diver EJ, Horowitz NS, Goldstein DP, Bernstein M, Berkowitz RS, Growdon WB. Timing of Referral to the New England Trophoblastic Disease Center: Does Referral with Molar Pregnancy Versus Postmolar Gestational Trophoblastic Neoplasia Affect Outcomes? J Reprod Med 2016; 61:187-91. PubMed